BioSpace News Archive

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the pricing of a global offering of ordinary shares, which may be represented by American Depository Shares.

This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.

Illumina Inc., a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC, a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, announced the five founding members of the Alliance for Genomic Discovery.

Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the Issuances of several of its important U.S. patents for NYMOZARFEX.

Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at the mRNA-Based Therapeutics Summit, occurring July 26-28, 2023 in Boston, MA.

BioNTX, the premier life science trade association in Texas is excited to announce that the Tech Transfer Office Showcase (TTOS) is back for a second year at the annual iC³ Life Science & Healthcare Innovation Summit on September 28th – 29th.

QIAGEN announced the expansion of its digital PCR offering for the development of cell and gene therapies in the biopharma industry.

Apogee Therapeutics, Inc. (Nasdaq: APGE) today announced the closing of its previously announced upsized initial public offering of 20,297,500 shares of common stock, including the full exercise of the underwriters’ option to purchase up 2,647,500 additional shares, at a public offering price of $17.00 per share.

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will report financial results for the second quarter 2023 on Monday, August 7, 2023.

Harrow (Nasdaq: HROW) and Novaliq GmbH today announced an agreement under which Harrow will acquire the U.S. and Canadian commercial rights for VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, ophthalmic solution prescription drug based on Novaliq’s proprietary EyeSol® water-free technology.